Retatrutide and trizepatide constitute a new class of medications that target both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These dual receptor agonists https://shaunaqovy539811.blog-mall.com/39408981/novel-glp-1-and-gip-receptor-agonists-retatrutide-and-trizepatide